Drug Profile
Research programme: cancer therapeutics - Netris Pharma
Alternative Names: Anti-SEMA3E monoclonal antibody - Netris Pharma; Anti-semaphorin 3E monoclonal antibody - Netris Pharma; Anti-TrkC monoclonal antibody - Netris Pharma; Anti-tropomyosin receptor kinase C monoclonal antibody - Netris Pharma; SEMA 3E - Netris PharmaLatest Information Update: 29 Sep 2023
Price :
$50
*
At a glance
- Originator Netris Pharma
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Semaphorin modulators; TrkC receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 Sep 2023 Research programme: cancer therapeutics is still in preclinical phase for Cancer in France (Netris Pharma pipeline, September 2023)
- 14 Dec 2016 Preclinical trials in Cancer in France (Parenteral) before December 2016